AAGP eNews
Feb. 10, 2015

New study echoes dementia dangers of allergy, sleep pills
By Denise A. Valenti
The physicians associated with the Alzheimer's Association recommend that those with dementia avoid over-the-counter medications that have diphenhydramine as the active ingredient. Diphenhydramine, an antihistamine that tends to make people drowsy, is in many allergy products, pain relievers, cold-and-sinus remedies as well as sleep aids that are available without a prescription. Of even greater concern is that anticholingergic drugs may actually produce or accelerate dementia and confusion.More

Next generation of dementia scientists to focus on lifestyle factors
Medical Xpress
Scottish scientists investigating the causes of dementia will study how lifestyle factors impact on memory and brain degeneration as seen in dementia. Four universities are to join forces to study how diet, exercise and other factors affect brain function and cognitive performance, blood flow and degeneration of brain tissue, and whether such changes are reversible.More

Study ties immune cells to delayed onset of post-stroke dementia
Stanford Medicine
A single stroke doubles a person's risk of developing dementia over the following decade, even when that person's mental ability is initially unaffected. Why this delayed deterioration occurs has been a mystery. Now, Stanford University School of Medicine investigators think they have discovered a major reason for it.More

Teaching children about Alzheimer's disease
The Huffington Post
While Alzheimer's disease can be difficult to talk about, there are more than 15 million Alzheimer's familial caregivers in the United States. Many of these individuals are children. Young people need to know about this condition, especially if their parents, grandparents or relatives receive a diagnosis. While it can be hard to talk to children about serious topics such as this, there are several approaches that can help make discussing Alzheimer's easier for all parties involved.More

Advocates say more money needed to fend off Alzheimer's epidemic
U.S. News & World Report
Scientists still need to learn more about Alzheimer's. They do not know, for example, whether it can conclusively be linked to heredity, though researchers have discovered that some genes increase the risk of getting Alzheimer's. Norman Relkin, a neurologist and neuroscientist at the Weill Cornell Medical College in New York, says research has not reached a dead end, however. In a time of need for additional research, advocates are turning to the federal government to spur innovation. More

Signs you're suffering from 'dementia of the preoccupied'
New York Magazine
In an interview this week on "Fresh Air," neuroscientist and author Frances Jensen introduces a much-needed phrase to the modern neurological lexicon: "dementia of the preoccupied." This, as you might've guessed, is not a real medical disorder; rather, it's a phrase Jensen came up with to describe the way she feels throughout the day, as she's constantly shifting her attention and switching between tasks. More

Report: Alzheimer's costs could soar to $1 trillion a year by 2050
The Washington Post
A report issued on the financial impact of Alzheimer’s disease in the United States warns that it could soar to more than $1 trillion a year by 2050, with much of it borne by the federal government, unless action is taken to shift current trends. The Alzheimer's Association report, "Changing the Trajectory of Alzheimer's Disease," urges the federal government to meet its own goals for research funding in a bid to find a cure or effective treatments by 2025. The U.S. could save $220 billion within the first five years if such treatments were found, the nonprofit's report says. Even with an interim treatment that slowed onset by five years, the costs would immediately drop as much as $535 billion over a 10-year period.More

New test claims it can tell if you will develop Alzheimer's ... but do you want to know?
Would you want to know if you are going to develop – or are already in pre-symptomatic early stages of – Alzheimer's disease? When there is currently no known cure and only marginal progress in symptomatic treatments, what good or harm comes from knowing? This hypothetical is one step closer to being your reality. More